Rezolute's RZ358 Shows Around 75% Reduction In Hypoglycemia Events

  • Rezolute Inc RZLT unveiled results from its Phase 2b RIZE study of RZ358 in patients with congenital hyperinsulinism (abnormally high insulin levels) at the Pediatric Endocrine Society 2022 Annual Meeting. 
  • RZ358 showed a better than 50% reduction from baseline in overall and severe hypoglycemia events and time in hypoglycemia in the pooled group of patients across all doses. 
  • A larger improvement of ~75% was seen at the anticipated therapeutic doses of 6 mg/kg and 9 mg/kg.
  • Also See: Rezolute Highlights Early-Stage Study Results For RZ402 In Diabetic Macular Edema.
  • RZ358 was generally safe and well-tolerated across the studied dose and age range. 
  • There were no adverse drug reactions, study discontinuations, or occurrences of clinically significant hyperglycemia. 
  • Additionally, Rezolute priced an underwritten registered direct offering of 18.03 million shares at $3.80/share and pre-funded warrants to purchase up to 12.9 million shares at $3.799/ pre-funded warrant. 
  • The company will use the gross proceeds of $130 million to develop RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema and other pipeline development, working capital, and general corporate purposes.
  • Price Action: RZLT shares closed 10.5% higher at $3.80 on Friday.

Posted In: BriefsPhase 2 TrialBiotechNewsPenny StocksHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.